Eton Pharma rises after securing US rights for rare disease drug

Eton Pharmaceuticals

19/05/2026 21:58

** Shares of Illinois-based drugmaker Eton Pharmaceuticals ETON.O rose 2% to $33.55 in extended trading

** Co says it has secured U.S. commercialization rights to rare disease drug Impavido from an affiliate of Knight Therapeutics

** The rights to the oral therapy, used to treat leishmaniasis, will take effect on September 26 - ETON

** Leishmaniasis is a rare disease transmitted by infected sand flies, which can cause severe skin lesions or infect internal organs if untreated

** The drug, which has been available in the United States since 2016, is indicated for adults and adolescents aged 12 years and older weighing more than 30 kg

** Up to last close, stock up 94.5% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))